$HIMS could be looking at a massive new opportunity. Leerink estimates the peptide telehealth market could reach $2.2 billion by 2027 and that Hims could capture roughly 20%. That would be about $440 million in potential annual revenue. And the broader non GLP-1 peptide opportunity could eventually reach $34 billion. Imagine how big this could become. 👀
在 X 查看 ↗